Head and Neck TumorsHead and Neck TumorsОпухоли головы и шеи2222-14682411-4634Publishing House ABV Press27110.17650/2222-1468-2017-7-2-99-105REVIEWSОБЗОРНЫЕ СТАТЬИNEW OPPORTUNITIES FOR IMMUNE THERAPY IN PATIENTS WITH DISSEMINATED RECURRENT SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECKНОВЫЕ ВОЗМОЖНОСТИ ИММУНОТЕРАПИИ В ЛЕЧЕНИИ РАСПРОСТРАНЕННОГО РЕЦИДИВНОГО ПЛОСКОКЛЕТОЧНОГО РАКА ОРГАНОВ ГОЛОВЫ И ШЕИMudunovA. M.МудуновА. М.
Russian Federation

23 Kashirskoe shosse, Moscow, 115478

115478 Москва, Каширское шоссе, 24

NarimanovM. N.НаримановМ. Н.
Russian Federation

23 Kashirskoe shosse, Moscow, 115478

Мехти Нариманович Нариманов.

115478 Москва, Каширское шоссе, 24

mehtin@mail.ruSafarovD. A.СафаровД. А.
Russian Federation

23 Kashirskoe shosse, Moscow, 115478

115478 Москва, Каширское шоссе, 24

N.N. Blokhin Russian Cancer Research Center, Ministry of Health of RussiaФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России2606201772991052706201727062017Copyright ©; 2017, Mudunov A.M., Narimanov M.N., Safarov D.A.Copyright ©; 2017, Мудунов А.М., Нариманов М.Н., Сафаров Д.А.2017Mudunov A.M., Narimanov M.N., Safarov D.A.Мудунов А.М., Нариманов М.Н., Сафаров Д.А.https://creativecommons.org/licenses/by/4.0https://ogsh.abvpress.ru/jour/article/view/271

Patients with head and neck squamous cell carcinoma diagnosed with recurrent tumor or distant metastases usually have the worst prognosis. Chemotherapeutic options are very limited in these patients; there is a probability of drug resistance development. The researchers continue to search more effective and less toxic drugs. In the current article, we analyze the results of the latest randomized clinical trials devoted the assessment of novel antitumor immunotherapeutic drugs – PD-1 inhibitors – in patients with head and neck squamous cell carcinoma. This studies reveal new possibilities for the treatment of these patients.

Пациенты с плоскоклеточным раком в области головы и шеи, у которых диагностированы рецидивные опухоли или отдаленные метастазы, имеют наихудший прогноз при данном заболевании. Возможности современной химиотерапии весьма ограничены у пациентов этой группы с перспективой постепенного развития резистентности к проводимой терапии. В связи с этим продолжается поиск более эффективных и менее токсичных препаратов.

В статье приводится анализ последних рандомизированных исследований по эффективности противоопухолевых препаратов нового поколения иммунотерапевтической направленности – ингибиторов PD-1 рецепторов у пациентов с плоскоклеточным раком головы и шеи. Полученные данные открывают новые возможности в лечении этой сложной группы пациентов.

head and neck tumorssquamous cell carcinomaPD-1immune therapynivolumabpembrolizumabопухоли головы и шеиплоскоклеточный ракPD-1иммунотерапияниволюмабпембролизумаб1. International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality, and prevalence worldwide in 2012. Available at: http://globocan.iarc.fr (accessed Jan 13, 2016).International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality, and prevalence worldwide in 2012. Available at: http://globocan.iarc.fr (accessed Jan 13, 2016).2. Seiwert T.Y., Salama J.K., Vokes E.E. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol 2007;4(3):156–71. DOI: 10.1038/ncponc0750. PMID: 17327856.Seiwert T.Y., Salama J.K., Vokes E.E. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol 2007;4(3):156–71. DOI: 10.1038/ncponc0750. PMID: 17327856.3. Vermorken J.B., Mesia R., Rivera F. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359(11):1116–27. DOI: 10.1056/NEJMoa0802656. PMID: 18784101.Vermorken J.B., Mesia R., Rivera F. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359(11):1116–27. DOI: 10.1056/NEJMoa0802656. PMID: 18784101.4. Seiwert T.Y., Zuo Z., Keck M.K. et al. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res 2015;21(3):632–41. DOI: 10.1158/1078–0432.CCR-13–3310. PMID: 25056374.Seiwert T.Y., Zuo Z., Keck M.K. et al. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res 2015;21(3):632–41. DOI: 10.1158/1078–0432.CCR-13–3310. PMID: 25056374.5. Keck M.K., Zuo Z., Khattri A. et al. Integrative analysis of head and neck cancer identifi es two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res 2015;21(4):870–81. DOI: 10.1158/1078–0432.CCR-14–2481. PMID: 25492084.Keck M.K., Zuo Z., Khattri A. et al. Integrative analysis of head and neck cancer identifi es two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res 2015;21(4):870–81. DOI: 10.1158/1078–0432.CCR-14–2481. PMID: 25492084.6. The Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517(7536):576–82. DOI: 10.1038/nature14129. PMID: 25631445.The Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517(7536):576–82. DOI: 10.1038/nature14129. PMID: 25631445.7. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677–704. DOI: 10.1146/annurev.immunol.26.021607.090331. PMID: 18173375.Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677–704. DOI: 10.1146/annurev.immunol.26.021607.090331. PMID: 18173375.8. Latchman Y., Wood C.R., Chernova T. et al. PD–L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Rev Immunol 2001;2 (3):261–68. DOI: 10.1038/85330. PMID: 11224527.Latchman Y., Wood C.R., Chernova T. et al. PD–L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Rev Immunol 2001;2 (3):261–68. DOI: 10.1038/85330. PMID: 11224527.9. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12(4):252–64. DOI: 10.1038/nrc3239. PMID: 22437870.Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12(4):252–64. DOI: 10.1038/nrc3239. PMID: 22437870.10. McDermott D. F., Atkins M.B. PD-1 as a potential target in cancer therapy. Cancer Med 2013;2(5):662–73. DOI: 10.1002/cam4.106. PMID: 24403232.McDermott D. F., Atkins M.B. PD-1 as a potential target in cancer therapy. Cancer Med 2013;2(5):662–73. DOI: 10.1002/cam4.106. PMID: 24403232.11. Lyford-Pike S., Peng S., Young G.D. et al. Evidence for a role of the PD-1: PD–L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 2013;73(6):1733–41. DOI: 10.1158/0008–5472.CAN-12–2384. PMID: 23288508.Lyford-Pike S., Peng S., Young G.D. et al. Evidence for a role of the PD-1: PD–L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 2013;73(6):1733–41. DOI: 10.1158/0008–5472.CAN-12–2384. PMID: 23288508.12. Saloura V., Zou Z., Koeppen H. Correlation of T-cell inflamed phenotype with mesenchymal subtype, expression of PD–L1, and other immune checkpoints in head and neck cancer. Proc Soc Am Clin Oncol 2014;32(5s): 6009 (abstr).Saloura V., Zou Z., Koeppen H. Correlation of T-cell inflamed phenotype with mesenchymal subtype, expression of PD–L1, and other immune checkpoints in head and neck cancer. Proc Soc Am Clin Oncol 2014;32(5s): 6009 (abstr).13. Ferris R., Blumenschein G., Fayette J. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016;375(19):1856–67. DOI: 10.1056/NEJMoa1602252. PMID: 27718784.Ferris R., Blumenschein G., Fayette J. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016;375(19):1856–67. DOI: 10.1056/NEJMoa1602252. PMID: 27718784.14. Hamid O., Robert C., Daud A. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369 (2):134–44. DOI: 10.1056/NEJMoa1305133. PMID: 23724846..Hamid O., Robert C., Daud A. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369 (2):134–44. DOI: 10.1056/NEJMoa1305133. PMID: 23724846..15. Garon E.B., Rizvi N.A., Hui R. et al. Pembrolizumab for the treatment of nonsmall-cell lung cancer. N Engl J Med 2015;372(21):2018–28. DOI: 10.1056/NEJMoa1501824. PMID: 25891174.Garon E.B., Rizvi N.A., Hui R. et al. Pembrolizumab for the treatment of nonsmall-cell lung cancer. N Engl J Med 2015;372(21):2018–28. DOI: 10.1056/NEJMoa1501824. PMID: 25891174.16. Topalian S.L., Hodi F.S., Brahmer J.R. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443–54. DOI: 10.1056/NEJMoa1200690. PMID: 22658127.Topalian S.L., Hodi F.S., Brahmer J.R. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443–54. DOI: 10.1056/NEJMoa1200690. PMID: 22658127.17. Bauml J., Siewert T., Pfister D.G. et al. Preliminary results from KEYNOTE-055: Pembrolizumab after Cisplatin and Cetuximab failure in Head and Neck squamous cell carcinoma. ASCO Annual Meeting, Best of ASCO designation: 2016. J Clin Oncol. 2016;34 (suppl): abstr 6011.Bauml J., Siewert T., Pfister D.G. et al. Preliminary results from KEYNOTE-055: Pembrolizumab after Cisplatin and Cetuximab failure in Head and Neck squamous cell carcinoma. ASCO Annual Meeting, Best of ASCO designation: 2016. J Clin Oncol. 2016;34 (suppl): abstr 6011.18. Machiels J.P., Haddad R.I., Fayette J. et al: Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol 2015;16(5):583–94. DOI: 10.1016/S1470–2045(15)70124–5. PMID: 25892145Machiels J.P., Haddad R.I., Fayette J. et al: Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol 2015;16(5):583–94. DOI: 10.1016/S1470–2045(15)70124–5. PMID: 2589214519. Seiwert T.Y., Fayette J., Cupissol D. et al. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol 2014;25(9):1813–20. DOI: 10.1093/annonc/mdu216. PMID: 24928832.Seiwert T.Y., Fayette J., Cupissol D. et al. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol 2014;25(9):1813–20. DOI: 10.1093/annonc/mdu216. PMID: 24928832.20. Chow L.Q. M., Haddad R., Gupta S. et al: Antitumor activity of pembrolizuamb in biomarker-unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: Results from the phase 1b KEYNOTE-012 expansion cohort. J Clin Oncol 2016;34:3838–45.Chow L.Q. M., Haddad R., Gupta S. et al: Antitumor activity of pembrolizuamb in biomarker-unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: Results from the phase 1b KEYNOTE-012 expansion cohort. J Clin Oncol 2016;34:3838–45.